Relationship Between Thyroid Dysfunction and Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-01

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the expression of glycemic parameters, lipid profile, and thyroid hormones in patients with type 2 diabetes mellitus in upper egypt.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy

NCT03178253

Hypothyroidism in Diabetes

UNKNOWN

Evaluation of the Pattern of Thyroid Dysfunctions in Patients With Metabolic Syndrome

NCT03214068

Metabolic Syndrome

COMPLETED

Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome

NCT06179368

Hepatic Encephalopathy Hepatic Impairment Hypothyroidism +1 more

RECRUITING

the Association Between Thyroid Hormones and Metabolic Components in Patients With Obesity

NCT04599374

Obesity Euthyroid Condition Metabolic Syndrome

COMPLETED

Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile

NCT07236697

Subclinical Hypothyroidism

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, resulting in persistent hyperglycemia. ( )..In T2DM, the response to insulin is diminished, and this is defined as insulin resistance. During this state, insulin is ineffective and is initially countered by an increase in insulin production to maintain glucose homeostasis, but over time, insulin production decreases, resulting in T2DM.( ).

Glycemic parameters are critical indicators for diagnosing and monitoring diabetes mellitus. The most commonly used measures include fasting blood glucose (FBG), postprandial blood glucose (PPBG), and glycated hemoglobin (HbA1c). Among them, HbA1c reflects the average blood glucose levels over the previous two to three months and is considered a reliable marker of chronic hyperglycemia.( ) Diabetic dyslipidemia constitutes a distinct cluster of plasma lipid and lipoprotein abnormalities that are metabolically interconnected in individuals with type 2 diabetes mellitus. This condition is predominantly characterized by elevated triglyceride (TG) concentrations, reduced levels of high-density lipoprotein cholesterol (HDL-C) ( ).

The underlying mechanism involves insulin resistance, which disrupts normal lipid metabolism by enhancing hepatic very low-density lipoprotein (VLDL) synthesis and impairing the clearance of triglyceride-rich lipoproteins. ( ) Prevalence of thyroid dysfunction is greater in diabetes patients compared to the general population.1-3 Prevalence of thyroid dysfunction in general population is around 6.6-13.4%, while in diabetes population around 10-24%.1 Studies found that subclinical hypothyroidism is the most common thyroid dysfunction in diabetic population ( ) Emerging evidence suggests a complex interplay between glycemic control, lipid metabolism, and thyroid function in patients with type 2 diabetes mellitus. Poor glycemic control has been associated with adverse lipid profiles and alterations in thyroid hormone levels, which may collectively contribute to the progression of diabetic complications. Thyroid hormones influence both glucose and lipid metabolism by regulating hepatic glucose production, lipolysis, and insulin sensitivity. ( ).

This study was conducted in Upper Egypt, a region characterized by distinct sociodemographic and health profiles compared to other parts of the country. Despite the growing burden of non-communicable diseases, including type 2 diabetes, there is a noticeable lack of regional epidemiological data addressing the coexistence of metabolic syndrome and thyroid dysfunction. Investigating this relationship in the Upper Egypt population may help fill existing knowledge gaps and support the development of more effective, geographically tailored healthcare strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus (T2DM) Thyroid Dysfunction Metabolic Syndrome Upper Egypt Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational cross-sectional study with no intervention.

This study does not involve any intervention. It is a cross-sectional observational study. The term "intervention" here refers to laboratory investigations and clinical assessments conducted as part of data collection only.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with type 2 diabetes mellitus in upper egypt.
* Age above 18 years.
* Patients who gave informed consent to participate.

Exclusion Criteria

* Patients with type 1 diabetes mellitus.
* Age below 18 years.
* Patients with known autoimmune thyroid diseases, pregnancy, or acute illness at the time of assessment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No